FDA Grants Priority Review for Dupilumab as Potential Treatment for Atopic Dermatitis in Adolescents

The FDA has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in adolescent patients aged 12 to 17 years with moderate-to-severe atopic dermatitis.

The FDA has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in adolescent patients aged 12 to 17 years with moderate-to-severe atopic dermatitis, according to an announcement issued by Regeneron Pharmaceuticals, Inc. and Sanofi. Currently, there are no FDA-approved systemic biologic medicines to treat adolescents with moderate-to-severe atopic dermatitis, according to the companies. If approved by the FDA, Dupixent would be indicated for those patients whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable.

The target action date for the FDA decision is March 11, 2019.

Dupixent is currently approved in the United States as a treatment for adults with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable; and as add-on maintenance treatment for patients 12 years and older with moderate-to-severe asthma with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. In 2016, the FDA granted Breakthrough Therapy designation for Dupixent for the treatment of moderate-to-severe (adolescents aged 12 to 17 years) and severe (children aged 6 months to 11 years) atopic dermatitis not well controlled on topical prescription medications.

FDA Accepts Dupilumab sBLA for Treatment of Asthma

Dupixent works by inhibiting interleukin-4 and interleukin-13 (IL-4 and IL-13) signaling, which is one of the important contributors to Type 2 inflammation, a systemic response known to play a role in moderate-to-severe atopic dermatitis.

The safety and efficacy of Dupixent in adolescents with atopic dermatitis have not been fully evaluated by any regulatory authority.

The new sBLA is supported by data from a pivotal Phase 3 trial evaluating the efficacy and safety of Dupixent monotherapy in adolescent patients with moderate-to-severe atopic dermatitis, which were presented at the European Academy of Dermatology and Venereology in September 2018.

Regeneron and Sanofi are also studying dupilumab in a broad range of clinical development programs for diseases driven by allergic and other Type 2 inflammation, including pediatric atopic dermatitis (Phase 3), pediatric asthma (Phase 3), chronic rhinosinusitis with nasal polyps (Phase 3), eosinophilic esophagitis (Phase 2/3), grass allergy (Phase 2) and peanut allergy (Phase 2). A future trial is planned for chronic obstructive pulmonary disease. Dupixent is also being studied in combination with REGN-3500, which targets IL-33. These potential uses are investigational, and the safety and efficacy have not been evaluated by any regulatory authority.

Positive Topline Results Shown for Dupilumab in Phase 3 Trials in Patients with CRSwNP

Dupilumab was discovered using Regeneron's proprietary VelocImmune® technology that yields optimized fully human antibodies, and is being jointly developed by Regeneron and Sanofi under a global collaboration agreement.

Reference

FDA Grants Priority Review for Dupixent® (dupilumab) as Potential Treatment for Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis [news release]. Tarrytown, NY and Paris; November 6, 2018: Regeneron and Sanofi. https://prnmedia.prnewswire.com/news-releases/fda-grants-priority-review-for-dupixent-dupilumab-as-potential-treatment-for-adolescents-with-uncontrolled-moderate-to-severe-atopic-dermatitis-300744235.html. Accessed November 6, 2018.